Published in Ann Rheum Dis on April 24, 2012
Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists. J Transl Med (2014) 0.90
Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) (2014) 0.82
Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis (2016) 0.80
Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis. Biologics (2014) 0.79
The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment. BMC Musculoskelet Disord (2015) 0.77
Herpes zoster infection risk in patients with rheumatoid arthritis on tumour necrosis factor inhibitors. Ann Rheum Dis (2013) 0.76
Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia. BMJ Open (2017) 0.75
Rheumatoid arthritis - an update for general dental practitioners. Br Dent J (2016) 0.75
What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis? Arthritis Res Ther (2016) 0.75
Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice. PLoS One (2017) 0.75
Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis. Open Forum Infect Dis (2016) 0.75
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 26.94
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol (1986) 5.82
Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum (2002) 4.69
Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum (2005) 4.64
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2006) 4.20
Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA (2009) 3.90
Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care (2007) 3.53
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum (2007) 3.38
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) (2010) 3.04
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis (2007) 2.53
Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis (2010) 1.87
The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol (2008) 1.64
Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis (2010) 1.59
The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther (2011) 1.33
The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford) (2008) 1.22
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum (2007) 3.99
Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum (2002) 3.53
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) (2010) 3.04
The epidemiology of chronic syndromes that are frequently unexplained: do they have common associated factors? Int J Epidemiol (2005) 2.48
Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum (2003) 2.20
Dietary risk factors for the development of inflammatory polyarthritis: evidence for a role of high level of red meat consumption. Arthritis Rheum (2004) 2.19
Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum (2005) 2.14
Immune reconstitution syndrome to Strongyloides stercoralis infection. AIDS (2007) 2.04
Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2011) 1.99
The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2012) 1.80
Prevalence and predictors of intense, chronic, and disabling neck and back pain in the UK general population. Spine (Phila Pa 1976) (2003) 1.79
Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2010) 1.77
No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2010) 1.73
Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum (2006) 1.72
Lateral wedge insoles as a conservative treatment for pain in patients with medial knee osteoarthritis: a meta-analysis. JAMA (2013) 1.67
Predictors of low back pain in British schoolchildren: a population-based prospective cohort study. Pediatrics (2003) 1.67
Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum (2002) 1.66
Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol (2009) 1.60
BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology (Oxford) (2011) 1.55
Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet (2013) 1.54
Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum (2011) 1.44
Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford) (2010) 1.43
Incidence of cancer among UK Gulf war veterans: cohort study. BMJ (2003) 1.43
The evolution of cellular deficiency in GATA2 mutation. Blood (2013) 1.36
The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis (2012) 1.30
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) (2010) 1.30
Predictors of hip joint replacement in new attenders in primary care with hip pain. Br J Gen Pract (2003) 1.29
Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis (2006) 1.25
When should the doctor order a spine X-ray? Identifying vertebral fractures for osteoporosis care: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2004) 1.24
Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis (2011) 1.24
Factors influencing the antibody response of dogs vaccinated against rabies. Vaccine (2007) 1.22
Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) (2013) 1.21
Dynamic consent: a possible solution to improve patient confidence and trust in how electronic patient records are used in medical research. JMIR Med Inform (2015) 1.19
The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence. Arthritis Rheum (2008) 1.18
Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum (2012) 1.17
Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum (2007) 1.16
A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum (2004) 1.16
Opportunities for prevention of 'clinically significant' knee pain: results from a population-based cross sectional survey. J Public Health (Oxf) (2004) 1.16
Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet (2008) 1.16
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther (2009) 1.15
Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Ann Rheum Dis (2012) 1.14
Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford) (2010) 1.13
Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs (2009) 1.11
Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford) (2009) 1.10
Determining aspects of ethnicity amongst persons of South Asian origin: the use of a surname-classification programme (Nam Pehchan). Public Health (2007) 1.09
Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthritis Care Res (Hoboken) (2010) 1.09
Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis (2010) 1.06
Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. Health Qual Life Outcomes (2010) 1.06
Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) (2012) 1.05
Serotype-specific immune unresponsiveness to pneumococcal conjugate vaccine following invasive pneumococcal disease. Infect Immun (2008) 1.03
BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology (Oxford) (2010) 1.02
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis (2012) 1.02
Primary care consultation predictors in men and women: a cohort study. Br J Gen Pract (2005) 1.02
Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol (2011) 1.02
Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis (2012) 1.01
Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis (2006) 1.01
Long-term mortality amongst Gulf War Veterans: is there a relationship with experiences during deployment and subsequent morbidity? Int J Epidemiol (2005) 1.01
Influence of inflammatory polyarthritis on cancer incidence and survival: results from a community-based prospective study. Arthritis Rheum (2007) 1.01
Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2009) 1.01
Agreement between proxy and adolescent assessment of disability, pain, and well-being in juvenile idiopathic arthritis. J Pediatr (2011) 1.00
Lumbar disc degeneration: association between osteophytes, end-plate sclerosis and disc space narrowing. Ann Rheum Dis (2006) 0.99
The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register. Rheumatology (Oxford) (2010) 0.98
Investigation of rheumatoid arthritis genetic susceptibility markers in the early rheumatoid arthritis study further replicates the TRAF1 association with radiological damage. J Rheumatol (2012) 0.98
The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. Ann Rheum Dis (2013) 0.98
Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2013) 0.94